Drug Trial Radar · NCT07703436
Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Mar 2027
Primary completion
Sep 2030
Study completion Mar 2032
Sponsor
- Lead sponsor
- Nuvation Bio Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will include up to 40 participants with Grade 2 or Grade 3 IDH1-mutant glioma who have undergone surgery and received vorasidenib as their only treatment, experienced radiographic disease progression on vorasidenib (confirmed by Blinded Independent Central Review \[BICR\] per modified Response Assessment in Neuro-Oncology \[RANO\] 2.0), and are not in need of immediate chemotherapy or radiotherapy.
Conditions
- Grade 2 IDH1-mutant Glioma
- Grade 3 IDH1-mutant Glioma
- Glioma
- IDH1-mutant Glioma
- Oligodendroglioma
- Oligodendroglioma IDH-1 Mutant and 1/p19q-codeleted
- Astrocytoma IDH Mutant Grade 3
- Astrocytoma IDH Mutant Grade 2
Interventions
SafusidenibDrug
Safusidenib administered twice daily as a single agent orally on Days 1 to 28 of a 28-day cycle. Participants may continue treatment until disease progression or another reason for discontinuation occurs.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) per modified Response Assessment in Neuro-Oncology (RANO) 2.0 assessed by Blinded Independent Central Review (BICR)Time frame: From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
University of California, Los Angeles
Los Angeles, California · Not yet recruiting
University of California, San Francisco
San Francisco, California · Not yet recruiting
Yale University
New Haven, Connecticut · Not yet recruiting
University of Miami Health
Miami, Florida · Not yet recruiting
Indiana University
Indianapolis, Indiana · Recruiting
LSU LCMC Health Cancer Center
New Orleans, Louisiana · Not yet recruiting
Massachusetts General Hospital
Boston, Massachusetts · Not yet recruiting
Rutgers Cancer Institute
New Brunswick, New Jersey · Not yet recruiting
NYU Langone Health
New York, New York · Recruiting
Columbia University Medical Center
New York, New York · Not yet recruiting
Cleveland Clinic
Cleveland, Ohio · Not yet recruiting
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.